Current Report Filing (8-k)
February 14 2020 - 5:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 14, 2020 (February 12, 2020)
DARIOHEALTH CORP.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37704
|
|
45-2973162
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
8 HaToKhen Street
Caesarea North Industrial Park
3088900, Israel
(Address of Principal
Executive Offices)
972-4-770-4055
(Issuer’s
telephone number)
(Former name or
former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which
registered
|
Common Stock, par value $0.0001 per share
|
|
DRIO
|
|
The Nasdaq Capital Market LLC
|
Warrants to purchase Common Stock
|
|
DRIOW
|
|
The Nasdaq Capital Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On
February 12, 2020, the Compensation Committee of the Board of Directors of DarioHealth Corp. approved a two (2) year extension
of the existing employment agreement of its Chief Executive Officer, Erez Raphael, such that it shall remain in effect through
December 31, 2022.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: February 14, 2020
|
DARIOHEALTH CORP.
|
|
|
|
By:
|
/s/ Zvi Ben David
|
|
|
Name: Zvi Ben David
Title: Chief Financial Officer, Treasurer and Secretary
|
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From Sep 2023 to Sep 2024